Case number 1:22-cv-00023
Novo Nordisk, Inc. et al v. Mylan Pharmaceuticals, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Aug 8, 2022 | N/A | Case Transfer Complete (0) Docket Text: Case Transfer Complete - Case transferred to District of Delaware on 8/5/2022. District of Delaware's case number is 1:22-cv-140. (jmm) |
| Aug 5, 2022 | 34 | Other Document (5) Docket Text: CERTIFIED COPY OF JPML CONDITIONAL TRANSFER ORDER re: pldg. ([1] in MDL No. 3038) Transferring 1 action(s) to Judge Colm F. Connolly in the D. Delaware. Signed by Judge Karen K. Caldwell, Chair, PANEL ON MULTIDISTRICT LITIGATION, on 8/5/2022. Associated Cases: MDL No. 3038, DE/1:22-cv-00294, DE/1:22-cv-00296, DE/1:22-cv-00297, DE/1:22-cv-00298, DE/1:22-cv-00299, WVN/1:22-cv-00023. (jmm) |
| Aug 5, 2022 | N/A | Case Transferred Out to Another District (0) Docket Text: Case transferred to the District of Delaware re MDL 3038. Entire Case file electronically transmitted. (jmm) |
| May 24, 2022 | 33 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [29] Motion of Olivia L. Wheeling for Leave to Appear Pro Hac Vice on behalf of Novo Nordisk, A/S, Novo Nordisk, Inc. Signed by District Judge John Preston Bailey on 5/24/2022. (dk) |
| May 24, 2022 | 32 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [28] Motion of Erica Sutter for Leave to Appear Pro Hac Vice on behalf of Novo Nordisk, A/S, Novo Nordisk, Inc. Signed by District Judge John Preston Bailey on 5/24/2022. (dk) |
| May 24, 2022 | 30 | Certificate of Service (2) Docket Text: CERTIFICATE OF SERVICE by Novo Nordisk, A/S Plaintiffs' Disclosure Pursuant to Rule 26(a)(1) of the Federal Rules of Civil Procedure (Companion, James) |
| May 19, 2022 | 29 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Olivia L. Wheeling by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| May 19, 2022 | 29 | Motion for Leave to Appear (Main Document) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Olivia L. Wheeling by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| May 19, 2022 | 28 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Erica R. Sutter by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Continued page for Application for Admission, # (2) Proposed Order)(Companion, James) |
| May 19, 2022 | 28 | Motion for Leave to Appear (Attachment Continued page for Application for Admission) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Erica R. Sutter by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Continued page for Application for Admission, # (2) Proposed Order)(Companion, James) |
| May 19, 2022 | 28 | Motion for Leave to Appear (Main Document) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Erica R. Sutter by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Continued page for Application for Admission, # (2) Proposed Order)(Companion, James) |
| May 16, 2022 | 27 | Report of Rule 26(f) Planning Meeting (22) Docket Text: REPORT of Rule 26(f) Planning Meeting. (White, Brandon) |
| May 11, 2022 | 26 | Notice of Appearance (2) Docket Text: NOTICE of Appearance by Gordon H. Copland on behalf of Mylan Pharmaceuticals, Inc. (Copland, Gordon) |
| May 11, 2022 | 25 | Other Document (Attachment Corrected Proof of Service) (4) Docket Text: Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Exhibit 1 to Corrected Schedule of Actions, # (2) Exhibit 2 to Corrected Schedule of Actions, # (3) Exhibit 3 to Corrected Schedule of Actions, # (4) Exhibit 4 to Corrected Schedule of Actions, # (5) Exhibit 5 to Corrected Schedule of Actions, # (6) Exhibit 6 to Corrected Schedule of Actions, # (7) Attachment Corrected Proof of Service)(Companion, James) |
| May 11, 2022 | 25 | Other Document (Exhibit 6 to Corrected Schedule of Actions) (30) Docket Text: Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Exhibit 1 to Corrected Schedule of Actions, # (2) Exhibit 2 to Corrected Schedule of Actions, # (3) Exhibit 3 to Corrected Schedule of Actions, # (4) Exhibit 4 to Corrected Schedule of Actions, # (5) Exhibit 5 to Corrected Schedule of Actions, # (6) Exhibit 6 to Corrected Schedule of Actions, # (7) Attachment Corrected Proof of Service)(Companion, James) |
| May 11, 2022 | 25 | Other Document (Exhibit 5 to Corrected Schedule of Actions) (30) Docket Text: Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Exhibit 1 to Corrected Schedule of Actions, # (2) Exhibit 2 to Corrected Schedule of Actions, # (3) Exhibit 3 to Corrected Schedule of Actions, # (4) Exhibit 4 to Corrected Schedule of Actions, # (5) Exhibit 5 to Corrected Schedule of Actions, # (6) Exhibit 6 to Corrected Schedule of Actions, # (7) Attachment Corrected Proof of Service)(Companion, James) |
| May 11, 2022 | 25 | Other Document (Exhibit 4 to Corrected Schedule of Actions) (30) Docket Text: Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Exhibit 1 to Corrected Schedule of Actions, # (2) Exhibit 2 to Corrected Schedule of Actions, # (3) Exhibit 3 to Corrected Schedule of Actions, # (4) Exhibit 4 to Corrected Schedule of Actions, # (5) Exhibit 5 to Corrected Schedule of Actions, # (6) Exhibit 6 to Corrected Schedule of Actions, # (7) Attachment Corrected Proof of Service)(Companion, James) |
| May 11, 2022 | 25 | Other Document (Exhibit 3 to Corrected Schedule of Actions) (30) Docket Text: Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Exhibit 1 to Corrected Schedule of Actions, # (2) Exhibit 2 to Corrected Schedule of Actions, # (3) Exhibit 3 to Corrected Schedule of Actions, # (4) Exhibit 4 to Corrected Schedule of Actions, # (5) Exhibit 5 to Corrected Schedule of Actions, # (6) Exhibit 6 to Corrected Schedule of Actions, # (7) Attachment Corrected Proof of Service)(Companion, James) |
| May 11, 2022 | 25 | Other Document (Exhibit 2 to Corrected Schedule of Actions) (30) Docket Text: Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Exhibit 1 to Corrected Schedule of Actions, # (2) Exhibit 2 to Corrected Schedule of Actions, # (3) Exhibit 3 to Corrected Schedule of Actions, # (4) Exhibit 4 to Corrected Schedule of Actions, # (5) Exhibit 5 to Corrected Schedule of Actions, # (6) Exhibit 6 to Corrected Schedule of Actions, # (7) Attachment Corrected Proof of Service)(Companion, James) |
| May 11, 2022 | 25 | Other Document (Exhibit 1 to Corrected Schedule of Actions) (30) Docket Text: Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Exhibit 1 to Corrected Schedule of Actions, # (2) Exhibit 2 to Corrected Schedule of Actions, # (3) Exhibit 3 to Corrected Schedule of Actions, # (4) Exhibit 4 to Corrected Schedule of Actions, # (5) Exhibit 5 to Corrected Schedule of Actions, # (6) Exhibit 6 to Corrected Schedule of Actions, # (7) Attachment Corrected Proof of Service)(Companion, James) |
| May 11, 2022 | 25 | Other Document (Main Document) (3) Docket Text: Courtesy copy of Corrected Schedule of Actions and Proof of Service Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Exhibit 1 to Corrected Schedule of Actions, # (2) Exhibit 2 to Corrected Schedule of Actions, # (3) Exhibit 3 to Corrected Schedule of Actions, # (4) Exhibit 4 to Corrected Schedule of Actions, # (5) Exhibit 5 to Corrected Schedule of Actions, # (6) Exhibit 6 to Corrected Schedule of Actions, # (7) Attachment Corrected Proof of Service)(Companion, James) |
| May 9, 2022 | 24 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER EXTENDING DEADLINE re [23]. The Court hereby ORDERS that the parties may submit their Joint Report of Initial Planning Meeting through and until May 16, 2022. Signed by District Judge John Preston Bailey on 5/9/2022. (dk) |
| May 9, 2022 | 23 | Motion for Miscellaneous Relief (Proposed Order) (1) Docket Text: Joint MOTION for Extension of Deadline to File the Joint Report of Initial Planning Meeting by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| May 9, 2022 | 23 | Motion for Miscellaneous Relief (Main Document) (3) Docket Text: Joint MOTION for Extension of Deadline to File the Joint Report of Initial Planning Meeting by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Attachment Oral Argument Statement) (2) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Attachment Proof of Service) (4) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Exhibit 6 to Schedule of Actions) (30) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Exhibit 5 to Schedule of Actions) (30) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Exhibit 4 to Schedule of Actions) (30) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Exhibit 3 to Schedule of Actions) (30) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Exhibit 2 to Schedule of Actions) (30) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Exhibit 1 to Schedule of Actions) (30) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Attachment Schedule of Actions) (2) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Attachment Opening Brief to Motion to Transfer) (21) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| May 6, 2022 | 22 | Other Document (Main Document) (7) Docket Text: Courtesy copy of Motion to Transfer Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Attachment Opening Brief to Motion to Transfer, # (2) Attachment Schedule of Actions, # (3) Exhibit 1 to Schedule of Actions, # (4) Exhibit 2 to Schedule of Actions, # (5) Exhibit 3 to Schedule of Actions, # (6) Exhibit 4 to Schedule of Actions, # (7) Exhibit 5 to Schedule of Actions, # (8) Exhibit 6 to Schedule of Actions, # (9) Attachment Proof of Service, # (10) Attachment Oral Argument Statement)(Companion, James) |
| Apr 29, 2022 | 21 | Answer to Counterclaim (30) Docket Text: PLAINTIFFS' ANSWER to [19] Answer to Complaint, Counterclaim by Novo Nordisk, A/S, Novo Nordisk, Inc..(Companion, James) |
| Apr 8, 2022 | 20 | Corporate Disclosure Statement (2) Docket Text: Corporate Disclosure Statement by Mylan Pharmaceuticals, Inc.. (White, Brandon) |
| Apr 8, 2022 | 19 | Answer to Complaint (30) Docket Text: ANSWER to [2] Complaint,, , COUNTERCLAIM against All Plaintiffs by Mylan Pharmaceuticals, Inc..(White, Brandon) |
| Mar 29, 2022 | 17 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [11] Motion for Leave to Appear Pro Hac Vice of Jeffrey Oelke. Signed by District Judge John Preston Bailey on 03/29/2022. (kam) |
| Mar 29, 2022 | 18 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [12] Motion for Leave to Appear Pro Hac Vice of Ryan Johnson. Signed by District Judge John Preston Bailey on 03/29/2022. (kam) |
| Mar 29, 2022 | 16 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [10] Motion for Leave to Appear Pro Hac Vice of Robert Counihan. Signed by District Judge John Preston Bailey on 03/29/2022. (kam) |
| Mar 29, 2022 | 15 | Order on Motion for Leave to Appear (1) Docket Text: ORDER granting [9] Motion for Leave to Appear Pro Hac Vice of Laura Moran. Signed by District Judge John Preston Bailey on 03/29/2022. (kam) |
| Mar 28, 2022 | 13 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE Returned Executed by Novo Nordisk, A/S, Novo Nordisk, Inc.. Mylan Pharmaceuticals, Inc. waiver sent on 3/24/2022, answer due 5/23/2022. (Companion, James) |
| Mar 28, 2022 | 12 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Ryan Johnson by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| Mar 28, 2022 | 12 | Motion for Leave to Appear (Main Document) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Ryan Johnson by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| Mar 28, 2022 | 11 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Jeffrey Oelke by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| Mar 28, 2022 | 11 | Motion for Leave to Appear (Main Document) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Jeffrey Oelke by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| Mar 28, 2022 | 10 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Robert Counihan by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| Mar 28, 2022 | 10 | Motion for Leave to Appear (Main Document) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Robert Counihan by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| Mar 28, 2022 | 9 | Motion for Leave to Appear (Proposed Order) (1) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Laura Moran by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| Mar 28, 2022 | 9 | Motion for Leave to Appear (Main Document) (2) Docket Text: MOTION for Leave to Appear Pro Hac Vice of Laura Moran by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Attachments: # (1) Proposed Order)(Companion, James) |
| Mar 28, 2022 | 8 | FirstOrder (4) Docket Text: FIRST ORDER AND NOTICE REGARDING DISCOVERY AND SCHEDULING: ***NOTICE TO ATTORNEYS*** : Pursuant to Rule 7.1 of the Federal Rules of Civil Procedure, ALL Non-governmental CORPORATE parties must file a DISCLOSURE STATEMENT with the Court. Forms are available on the Court's Web Site at http://www.wvnd.uscourts.gov/forms.htm Rule 26 Meeting to be held by 4/25/2022. Rule 26 Meeting Report due by 5/9/2022. Discovery due by 5/23/2022. Signed by District Judge John Preston Bailey on 3/28/2022. (dk) |
| Mar 25, 2022 | 7 | Order Reassigning Case (1) Docket Text: ORDER. Case reassigned to District Judge John Preston Bailey for all further proceedings. Senior Judge Irene M. Keeley no longer assigned to case. Signed by Senior Judge Irene M. Keeley on 03/25/2022. (kam) |
| Mar 18, 2022 | 6 | Other Document (2) Docket Text: Supplemental ANDA Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Companion, James) |
| Mar 18, 2022 | 5 | Other Document (2) Docket Text: Disclosure Statement Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Companion, James) |
| Mar 18, 2022 | 4 | Notice of Verification of Attorney Admission (1) Docket Text: VERIFICATION OF ATTORNEY ADMISSION to Attorneys J. Oelke, L. Moran, R. Johnson, and R. Counihan. (to Oelke, Moran, and Johnson by NEF; to R. Counihan by U.S. mail) (dk) |
| Mar 18, 2022 | 3 | Report Re: Patent/Trademark (2) Docket Text: REPORT to USPTO on the filing or determination of an action regarding re [2] Complaint. (dk) |
| Mar 18, 2022 | 2 | Complaint (Civil Cover Sheet) (2) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit R - 363 Patent) (16) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit Q - 063 Patent) (7) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit P - 652 Patent) (21) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit O - 616 Patent) (24) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit N - 462 Patent) (26) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit M - 155 Patent) (7) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit L - 757 Patent) (23) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit K - 953 Patent) (16) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit J - 611 Patent) (13) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit I - 180 Patent) (21) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit H - 154 Patent) (25) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit G - 239 Patent) (9) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit F - 002 Patent) (20) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit E - 383 Patent) (15) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit D - 969 Patent) (14) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit C - 122 Patent) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit B - 343 Patent) (30) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Exhibit A - 833 Patent) (23) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 2 | Complaint (Main Document) (25) Docket Text: COMPLAINT against Mylan Pharmaceuticals, Inc., filed by Novo Nordisk, A/S, Novo Nordisk, Inc. Filing Fee Paid $402. Receipt #AWVNDC-3445410. (Attachments: # (1) Exhibit A - 833 Patent, # (2) Exhibit B - 343 Patent, # (3) Exhibit C - 122 Patent, # (4) Exhibit D - 969 Patent, # (5) Exhibit E - 383 Patent, # (6) Exhibit F - 002 Patent, # (7) Exhibit G - 239 Patent, # (8) Exhibit H - 154 Patent, # (9) Exhibit I - 180 Patent, # (10) Exhibit J - 611 Patent, # (11) Exhibit K - 953 Patent, # (12) Exhibit L - 757 Patent, # (13) Exhibit M - 155 Patent, # (14) Exhibit N - 462 Patent, # (15) Exhibit O - 616 Patent, # (16) Exhibit P - 652 Patent, # (17) Exhibit Q - 063 Patent, # (18) Exhibit R - 363 Patent, # (19) Civil Cover Sheet)(dk) |
| Mar 18, 2022 | 1 | Other Document (2) Docket Text: REPORT ON FILING ACTION RE PATENT Other Document filed by Novo Nordisk, A/S, Novo Nordisk, Inc.. (Companion, James) |
